Published TCIMAIL newest issue No.197
Maximum quantity allowed is 999
Please select the quantity
Glycogen Synthase Kinase (GSK) Inhibitor
No.172(January 2017)
Glycogen synthase kinase-3 (GSK-3) is a serine/threonine kinase and was first isolated from rabbit skeletal muscle.1) There are two isoforms of mammalian GSK-3, including GSK-3α and GSK-3β, which are encoding by separate genes (GSK3A, GSK3B).2) GSK-3 is associated with various signaling pathways including the wnt/β-catenin pathway.3)
A large number of GSK-3 inhibitors have been reported and classified into two types, ATP-competitive and non-ATP-competitive inhibitors.4) TDZD-8 (Thiadiazolidine-8, 1) is a non-ATP-competitive inhibitor of GSK-3β (Study I in the Table).5) Interestingly, in the study using PKC isoforms, it is shown that PKCβ 1, PKCδ, and PKCι are also inhibited by 1 (Study II in the Table).6)
References
- 1)Glycogen synthase kinase-3 from rabbit skeletal muscle, separation from cyclic-AMP-dependent protein kinase and phosphorylase kinase
- 2)Molecular cloning and expression of glycogen synthase kinase-3/Factor A
- 3)GSK-3: Tricks of the trade for a multi-tasking kinase
- 4)Glycogen synthase kinase-3 (GSK-3)-targeted therapy and imaging
- 5)First non-ATP competitive glycogen synthase kinase 3β (GSK-3β) inhibitors: Thiadiazolidinones (TDZD) as potential drugs for the treatment of Alzheimer’s disease
- 6)Rapid and selective death of leukemia stem and progenitor cells induced by the compound 4-benzyl, 2-methyl, 1,2,4-thiadiazolidine, 3,5 dione (TDZD-8)
The prices are subject to change without notice. Please confirm the newest price by our online catalog before placing an order.
In addition, sales products changes with areas. Please understand that a product is not available when the product details page is not displayed.
In addition, sales products changes with areas. Please understand that a product is not available when the product details page is not displayed.